Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2025 08:00 ET | Source: BrainsWay

BrainsWay Reports National Institutes of Health Grant to Leading U.S. Research Team Investigating Accelerated Deep TMS for Treatment of Alcohol Use Disorder

BURLINGTON, Mass. and JERUSALEM, Nov. 04, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
October 28, 2025 08:00 ET | Source: BrainsWay

BrainsWay to Report Third Quarter 2025 Financial Results on November 11, 2025

BURLINGTON, Mass. and JERUSALEM, Oct. 28, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
October 27, 2025 07:30 ET | Source: BrainsWay

BrainsWay Announces Additional Minority-Stake Investments in Leading U.S. Mental Health Providers

Recent agreements with two additional U.S. mental health providers bring total to four in 2025 Strategy seeks to drive long-term shareholder value BURLINGTON, Mass. and JERUSALEM, Oct. 27, 2025 ...
September 16, 2025 08:30 ET | Source: BrainsWay

BrainsWay Receives FDA Clearance for Accelerated Deep TMS Protocol for Non-Invasive Treatment of Major Depressive Disorder (MDD)

Clinical data shows that BrainsWay’s new accelerated stimulation protocol is comparable to standard Deep TMS in depression score improvement, response and remission The accelerated protocol is now...
August 21, 2025 07:30 ET | Source: BrainsWay

BrainsWay Targets Expansion of its Total Addressable Market through a Strategic Investment in Neuromodulation Systems Developer, Neurolief Ltd.

This investment marks BrainsWay’s entrance into the market for mental health therapies that can be administered outside of a clinic, including at home Neurolief’s breakthrough Proliv™Rx device is...
August 20, 2025 07:30 ET | Source: BrainsWay

BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health

BURLINGTON, Mass. and JERUSALEM, Aug. 20, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
August 13, 2025 07:30 ET | Source: BrainsWay

BrainsWay Reports Second Quarter 2025 Financial Results and Operational Highlights

Achieved record quarterly revenue of $12.6 million in Q2 2025, an increase of 26% compared to Q2 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.5 million, Raised...
July 30, 2025 09:02 ET | Source: BrainsWay

BrainsWay Champions TMS Education with Sponsorship of Two Free CME Courses for Mental Health Professionals

BURLINGTON, Mass. and JERUSALEM, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- BrainsWay, a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, is proud to...
July 30, 2025 08:00 ET | Source: BrainsWay

BrainsWay to Report Second Quarter 2025 Financial Results on August 13, 2025

BURLINGTON, Mass. and JERUSALEM, July 30, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
June 11, 2025 07:30 ET | Source: BrainsWay

BrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD)

BURLINGTON, Mass. and JERUSALEM, June 11, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health...